Cervomed announces completion of enrollment in phase 2b rewind-lb clinical trial of neflamapimod for the treatment of patients with dementia with lewy bodies

- topline data expected in december 2024 - - phase 2b design optimized for success; clear path to market in this high value indication expected with positive result - boston, june 11, 2024 (globe newswire) -- cervomed inc. (nasdaq: crvo), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that it has completed enrollment in rewind-lb, a phase 2b trial evaluating neflamapimod in patients with dementia with lewy bodies (dlb). “drug development for the major dementias over the past decade has progressively focused on earlier stages of disease.
CRVO Ratings Summary
CRVO Quant Ranking